Published on: November 5, 2014
by AAP for Nursing Careers Allied Health:
Men under 1.68m in height are 50 per cent more likely to suffer death from Alzheimer’s or other forms of dementia than those taller than 1.78m.
Being short increases a person’s chances of dying from dementia, new research has shown.
Men less than 1.68m in height are 50 per cent more likely to suffer death from Alzheimer’s or other forms of dementia than those taller than 1.78m.
Women are less at risk, but those shorter than 1.55m are still 35 per cent more likely to have their lives ended by the disease than those taller than 1.65m.
Scientists analysed findings from 18 studies with more than 180,000 participants, comparing the risk of dying from dementia for the tallest and shortest men and women.
They stressed there was no evidence that lack of height triggered the brain-deteriorating condition, the most common form of which is Alzheimer’s.
But height could be a marker of other factors that might influence dementia risk.
Senior author Dr David Batty, of University College London, said: “Short height in itself of course does not ’cause’ dementia. Rather, height captures a number of early life factors, including early-life illness, adversity, poor nutrition and psychosocial stress, and so allows us to examine the effect of these factors on dementia more closely.”
Study leader Dr Tom Russ, of the University of Edinburgh, said: “The association between height and dementia death remained when we took into account early life or adult socioeconomic status and other relevant factors, including obesity, smoking, cardiovascular disease risk factors and longstanding illness.”
Our event with Dr. Wendy Suzuki explaining how higher levels of physical fitness are associated with better brain structure and higher cognitive function. Highlights video.
Our event with Dr. Wendy Suzuki explaining how higher levels of physical fitness are associated with better brain structure and higher cognitive function. Full video.
Two blood markers, phosphorylated tau 217 (p-tau217) and phosphorylated tau 181 (p-tau181), showed strong diagnostic performances for Alzheimer’s disease and discriminated Alzheimer’s from frontotemporal lobar denervation (FTLD) syndromes and normal cognition, a retrospective study...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.